Q3FY25 results showcase a solid performance for Indegene Limited, with revenue from operations reaching ₹7,204 million, reflecting a 4.9% QoQ and 7.0% YoY growth.

The EBITDA margin improved to 20.8%, driven by operational efficiencies and stronger client engagements, while the PAT margin rose to 15.2% with profit after tax increasing to ₹1,097 million, marking a 19.6% sequential growth.

Notably, engagement with large pharma customers remains robust, contributing to a steady revenue stream.

The company is well-positioned within a growing life sciences market, leveraging advances in digital tools and analytics.

With active clients numbering 75, the outlook remains positive as they continue to deepen relationships with key accounts.

Monitoring operational metrics like customer concentration and employee efficiency will be essential for investors looking for continued growth trajectory.